Download or read book Pharmaceutical Innovation promises and Problems written by United States. Congress. House. Committee on Science and Technology. Subcommittee on Natural Resources, Agriculture Research, and Environment and published by . This book was released on 1982 with total page 248 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Pharmaceutical Innovation promises and Problems written by United States. Congress. House. Committee on Science and Technology. Subcommittee on Natural Resources, Agriculture Research, and Environment and published by . This book was released on 1982 with total page 260 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Pharmaceutical Innovation promises and Problems written by United States. Congress. House. Committee on Science and Technology. Subcommittee on Natural Resources, Agriculture Research, and Environment and published by . This book was released on 1982 with total page 237 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Pharmaceutical Economics and Policy written by Stuart O. Schweitzer and published by Oxford University Press. This book was released on 2018 with total page 433 pages. Available in PDF, EPUB and Kindle. Book excerpt: The pharmaceutical industry -- The biotechnology industry -- Generics and biosimilars -- The global pharmaceutical industry -- The demand for pharmaceuticals -- The demand for pharmaceuticals in major international markets -- Pharmaceutical prices -- Economic evaluation of new drugs -- Pricing pharmaceuticals in a world environment -- Pharmaceutical marketing -- Patent protection -- Drug approval process in the United States -- Pharmaceutical regulation in the European Union -- Pharmaceuticals and public policy : a look ahead
Download or read book Leading Pharmaceutical Innovation written by Oliver Gassmann and published by Springer Science & Business Media. This book was released on 2008-02-19 with total page 194 pages. Available in PDF, EPUB and Kindle. Book excerpt: Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D.
Download or read book Paper Promises for Drug Innovation written by Erika Lietzan and published by . This book was released on 2019 with total page 48 pages. Available in PDF, EPUB and Kindle. Book excerpt: Innovation does not stop when a new medicine is launched. Development of new uses for already approved drugs, in particular, can make profound contributions to the public health. Whether a new use is suspected during the initial premarket trials, identified through focused research after approval, or discovered serendipitously by physicians treating patients, however, it requires extensive clinical testing before it can be approved by FDA. This testing takes time and money -- three to five years on average, and as much as $300 million. This Article considers the incentives that federal law offers to companies to make this investment: patent protection and regulatory exclusivity. Both are designed to provide the innovator with a temporary period of exclusive sales for the use in question. In theory, a generic should be dispensed for all other uses, but the innovator should enjoy all sales for the new use. In fact, though, the sales are not excludable; the incentives are nothing more than paper promises. Generic companies generally enjoy the new-use sales as well. This is flatly inconsistent with the goal of the federal laws governing new-use patents and new-use regulatory exclusivity, and it needs to stop. It happens because we have acquiesced to FDA practices and policies, state laws and policies, and healthcare professional and payer behaviors that work together to gut the incentives put in place by Congress. This Article considers ways of reforming practices at the agency and elsewhere in the healthcare system, so that we can have prompt approval of lower cost generic drugs when patents and exclusivity on a brand drug's underlying compound and initial use expire, and automatic substitution of those generics when the brand drug is prescribed for the initial use, without the gutting of incentives enacted by Congress.
Download or read book Leading Pharmaceutical Innovation written by Oliver Gassmann and published by Springer. This book was released on 2019-01-12 with total page 179 pages. Available in PDF, EPUB and Kindle. Book excerpt: Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D.
Download or read book AI in Pharma written by Tantrajnana Vedike and published by Independently Published. This book was released on 2024-08-03 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: In the rapidly evolving landscape of pharmaceuticals, the advent of artificial intelligence (AI) has marked a transformative era, reshaping the way we understand and approach drug discovery, development, and delivery. "AI in Pharma" seeks to explore this groundbreaking shift, offering a comprehensive examination of how AI technologies are revolutionizing the pharmaceutical industry. The journey of integrating AI into pharma is not just a tale of technological advancement; it is a narrative of innovation that promises to redefine the future of medicine. From accelerating drug discovery and personalizing treatment regimens to optimizing clinical trials and improving patient outcomes, AI holds the potential to address some of the most pressing challenges in healthcare today. This book is born from a convergence of expertise in both the pharmaceutical sciences and artificial intelligence. We have meticulously curated insights from industry leaders, researchers, and practitioners to provide a multifaceted perspective on the ways AI is being harnessed in this critical field. Each chapter delves into specific applications of AI, offering a blend of theoretical frameworks and practical case studies that illuminate the real-world impact of these technologies. "AI in Pharma" is designed to be a valuable resource for a diverse audience. For industry professionals and researchers, it offers a deep dive into current AI applications and future trends, providing actionable insights and fostering a deeper understanding of how these technologies can be leveraged to drive innovation. For students and newcomers, it presents foundational knowledge and emerging opportunities in a rapidly growing field. And for policymakers and stakeholders, it highlights the implications of AI advancements and the need for thoughtful integration and regulation. As we embark on this exploration, we acknowledge the profound responsibility that comes with the integration of AI into healthcare. The promise of AI is accompanied by challenges and ethical considerations that must be navigated with care. Our hope is that this book not only informs but also inspires meaningful dialogue and collaborative efforts to harness AI's full potential while upholding the highest standards of safety, equity, and integrity. In this dynamic era of technological transformation, "AI in Pharma" serves as both a guide and a catalyst, encouraging readers to envision the future of pharmaceutical innovation through the lens of artificial intelligence. As we turn these pages, let us embrace the possibilities that AI offers and work together to shape a future where advanced technology and human ingenuity combine to deliver groundbreaking solutions in medicine. Welcome to a new chapter in pharmaceuticals-one that is powered by intelligence, innovation, and the relentless pursuit of better health for all.
Download or read book Pharmaceutical Innovation written by Ralph Landau and published by Chemical Heritage Foundation. This book was released on 1999 with total page 458 pages. Available in PDF, EPUB and Kindle. Book excerpt: Documents how science has provided an astonishing array of medicines for coping with human ailments. This volume addresses industry leaders, economic influences, and the development of individual products. It is suitable for policy makers, economists, corporate executives, research managers, and historians of science, technology, and medicine.
Download or read book Devalued and Distrusted written by John L. LaMattina and published by John Wiley & Sons. This book was released on 2012-12-10 with total page 173 pages. Available in PDF, EPUB and Kindle. Book excerpt: An expert's view on solving the challenges confronting today's pharmaceutical industry Author John LaMattina, a thirty-year veteran of the pharmaceutical industry and former president of Pfizer's Global R&D Division, is internationally recognized as an expert on the pharmaceutical industry. His first book, Drug Truths: Dispelling the Myths About Pharma R&D, was critically acclaimed for clearing up misconceptions about the pharmaceutical industry and providing an honest account of the contributions of pharmaceutical research and development to human health and well-being. As he toured the country discussing Drug Truths, Dr. LaMattina regularly came across people who were filled with anger, accusing the pharmaceutical industry of making up diseases, hiding dangerous side effects, and more. This book was written in response to that experience, critically examining public perceptions and industry realities. Starting with "4 Secrets that Drug Companies Don't Want You to Know," Devalued and Distrusted provides a fact-based account of how the pharmaceutical industry works and the challenges it faces. It addresses such critical issues as: Why pharmaceutical R&D productivity has declined Where pharmaceutical companies need to invest their resources What can be done to solve core health challenges, including cancer, diabetes, and neurodegenerative diseases How the pharmaceutical industry can regain public trust and resuscitate its image Our understanding of human health and disease grows daily; however, converting science into medicine is increasingly challenging. Reading Devalued and Distrusted, you'll not only gain a greater appreciation of those challenges, but also the role that the pharmaceutical industry currently plays and can play in solving those challenges. Get to know the author: Read an interview with John LaMattina or watch a video on ChemistryViews! Interview: John LaMattina: 30 Years in Pharma Video: Can the Pharmaceutical Industry Restory its Broken Image?
Download or read book Pharmaceutical Economics and Policy written by Stuart O. Schweitzer and published by Oxford University Press. This book was released on 2007 with total page 362 pages. Available in PDF, EPUB and Kindle. Book excerpt: Publisher description
Download or read book Improving and Accelerating Therapeutic Development for Nervous System Disorders written by Institute of Medicine and published by National Academies Press. This book was released on 2014-02-06 with total page 107 pages. Available in PDF, EPUB and Kindle. Book excerpt: Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.
Download or read book Pharmaceutical Innovation After World War II From Rational Drug Discovery to Biopharmaceuticals written by Apostolos Zarros and published by Frontiers Media SA. This book was released on 2019-11-27 with total page 137 pages. Available in PDF, EPUB and Kindle. Book excerpt: This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact.
Download or read book Modern Methods of Clinical Investigation written by Institute of Medicine and published by National Academies Press. This book was released on 1990-02-01 with total page 241 pages. Available in PDF, EPUB and Kindle. Book excerpt: The very rapid pace of advances in biomedical research promises us a wide range of new drugs, medical devices, and clinical procedures. The extent to which these discoveries will benefit the public, however, depends in large part on the methods we choose for developing and testing them. Modern Methods of Clinical Investigation focuses on strategies for clinical evaluation and their role in uncovering the actual benefits and risks of medical innovation. Essays explore differences in our current systems for evaluating drugs, medical devices, and clinical procedures; health insurance databases as a tool for assessing treatment outcomes; the role of the medical profession, the Food and Drug Administration, and industry in stimulating the use of evaluative methods; and more. This book will be of special interest to policymakers, regulators, executives in the medical industry, clinical researchers, and physicians.
Download or read book Science Business written by Gary P. Pisano and published by Harvard Business Press. This book was released on 2006 with total page 278 pages. Available in PDF, EPUB and Kindle. Book excerpt: Why has the biotechnology industry failed to perform up to expectations? This book attempts to answer this question by providing a critique of the industry. It reveals the causes of biotech's problems and offers an analysis on how the industry works. It also provides prescriptions for companies, seeking ways to improve the industry's performance.
Download or read book Preserving the Promise written by Scott Dessain and published by Academic Press. This book was released on 2016-10-05 with total page 277 pages. Available in PDF, EPUB and Kindle. Book excerpt: Preserving the Promise: Improving the Culture of Biotech Investment critically examines why most biotech startups fail, as they emerge from universities into an ecosystem that inhibits rather than encourages innovation. This "Valley of Death" squanders our public investments in medical research and with them, the promise of longer and healthier lives. The authors explicate the Translation Gap faced by early stage biotech companies, the result of problematic technology transfer and investment practices, and provide specific prescriptions for improving translation of important discoveries into safe and effective therapies. In Preserving the Promise, Dessain and Fishman build on their collective experience as company founders, healthcare investor (Fishman) and physician/scientist (Dessain). The book offers a forward-looking, critical analysis of "conventional wisdom" that encumbers commercialization practices. It exposes the self-defeating habits of drug development in the Valley of Death, that waste money and extinguish innovative technologies through distorted financial incentives. Explains why translation of biotech discovery into medicine succeeds so infrequently that it’s been dubbed the Valley of Death Uncovers specific decision-making strategies that more effectively align incentives, improving clinical and financial outcomes for investors, inventor/entrepreneurs, and patients Examines the critical, early stages of commercialization, where technology transfer offices and Angels act as gatekeepers to development, and where tension between short-term financial and long-term clinical aspirations sinks important technologies Deconstructs the forces driving biotech, recasts them in a proven conceptual framework, and offers practical guidance for making the system better
Download or read book Monthly Catalog of United States Government Publications written by and published by . This book was released on with total page 912 pages. Available in PDF, EPUB and Kindle. Book excerpt:
